Identifying therapeutic targets for erectile dysfunction in the European population using genome-wide Mendelian...

Area of Science:

• Genetics and Pharmacology
• Bioinformatics and Computational Biology

Background:

• Erectile dysfunction (ED) is a common condition with limited treatment options.
• Current ED therapies face challenges with efficacy and side effects.
• Mendelian randomization (MR) presents a novel approach for identifying genetic targets for new ED therapies.

Purpose of the Study:

• To conduct a genome-wide MR study to identify druggable genes for novel erectile dysfunction (ED) therapies.
• To pinpoint genes associated with ED and explore their therapeutic potential.

Main Methods:

• Genome-wide association studies (GWAS) data for drug-targetable genes and expression quantitative trait loci (eQTLs) were utilized.
• Two-sample MR analysis was performed to identify genes linked to ED.
• Enrichment analysis, protein-protein interaction network construction, and drug prediction were conducted.

Main Results:

• The MR analysis identified 124 genes significantly associated with ED.
• Enrichment analysis highlighted involvement in signal transduction, protein phosphorylation, plasma membrane, cytoplasm, ATP binding, and the PI3K-Akt pathway.
• Top hub genes (e.g., PRKCA, IFNG, ITGB1) were identified, with potential drug repurposing candidates like benztropine, teplizumab, and natalizumab suggested.

Conclusions:

• The study successfully mapped druggable genes and pathways implicated in ED through MR.
• Identified high-priority targets and approved drugs offer opportunities for rapid repurposing trials.
• This research advances precision medicine for ED by providing actionable drug repurposing candidates.